Core Viewpoint - The recent investment cooperation agreement between China National Pharmaceutical Group (国药集团) and Shandong Pharmaceutical Glass Co., Ltd. (山东药玻) marks a significant shift in the company's ownership structure, potentially enhancing its operational capabilities and market position in the pharmaceutical packaging industry [1][3]. Company Overview - Shandong Pharmaceutical Glass, established in 1970 and listed in June 2002, has developed a comprehensive range of pharmaceutical packaging products, including bottles, stoppers, and caps, becoming a leading manufacturer in the industry [5]. - In Q1 2025, the company reported revenues of 1.242 billion yuan and a net profit attributable to shareholders of 224 million yuan [5]. Investment Details - On June 20, 2023, an investment cooperation agreement was signed, where China National Pharmaceutical Group and its subsidiaries will inject 2.449 billion yuan into Shandong Pharmaceutical Glass's indirect controlling shareholder, Shandong Luzhong Investment Co., Ltd. (鲁中投资), acquiring a 51% stake [1]. - This transaction will change the indirect controlling shareholder from Luzhong Holdings to China National Pharmaceutical Group, with the actual controller shifting from the Yiyuan County Finance Bureau to China National Pharmaceutical Group [1]. Strategic Implications - The partnership aims to enhance the modernization of the industrial system and improve the competitiveness of the pharmaceutical and health industry in Yiyuan County and Zibo City [3]. - The acquisition is seen as a strategic move for China National Pharmaceutical Group to expand its presence in the upstream pharmaceutical supply chain, particularly in the pharmaceutical packaging materials sector [3][5]. Challenges and Opportunities - Despite steady growth, Shandong Pharmaceutical Glass faces challenges such as the need for capital, technology, and management upgrades to further its development [4]. - The collaboration with China National Pharmaceutical Group is expected to provide substantial financial support, access to global marketing networks, and technological advancements, which could significantly enhance the company's competitive edge and contribute to the growth of the local pharmaceutical industry [5].

Group 1 - Honor's new AI foldable flagship phone, Magic V5, is set to be released on July 2, 2025, and is positioned as the "lightest foldable phone globally" and "the strongest AI smartphone in the industry" [1] - The Magic V5 will feature a Snapdragon 8 Gen 2 processor, a new silicon battery, and support for Beidou satellite messaging and side fingerprint recognition [1] - Apple is expected to start production of its foldable iPhone in Q3 or Q4 of 2025, with orders for 15 to 20 million units, indicating a long-term demand outlook rather than just for 2026 [1] Group 2 - The foldable smartphone market is anticipated to be a key growth area as the overall smartphone market slows down, with a projected global shipment growth rate of 6% for foldable phones in 2023 [2] - China is leading the foldable smartphone industry, accounting for 46% of global shipments from Q1 to Q3 of 2024 [2] Group 3 - On August 9, 2024, speculation arose about Huawei launching a new three-fold phone, leading to significant stock price increases for several foldable concept stocks, including Star Technology and Kaisheng Technology [3] - Notable stock performances included Star Technology with a 20.23% increase, Huawei Technology with a 10.05% increase, and Kaisheng Technology with a 10% increase [4]

Core Viewpoint - The legal opinion letter from Shanghai Tianyanhe Law Firm confirms that the stock option incentive plan for Kaisheng Technology Co., Ltd. has obtained the necessary approvals and complies with relevant laws and regulations [1][10]. Group 1: Approval and Decision-Making Process - The company has completed the necessary approval and decision-making processes for the stock option incentive plan, including discussions and approvals from the board and supervisory committee [5][6]. - The plan received approval from the State-owned Assets Supervision and Administration Commission, allowing the implementation of the stock option incentive plan [5][6]. - The supervisory committee verified the list of incentive recipients and provided opinions on the public disclosure of the plan [6][10]. Group 2: Specifics of the Grant - The grant date for the stock options is determined by the board of directors, and the plan allows for the granting of options to 194 recipients, totaling 16.3 million stock options [7][8]. - The exercise price for the stock options has been adjusted from 12.13 yuan per share to 12.08 yuan per share following a profit distribution [8][10]. - The granting conditions require that recipients meet specific criteria, ensuring compliance with the management regulations and the incentive plan [9][10]. Group 3: Conclusion - The legal opinion concludes that the stock option incentive plan's grant date, recipients, quantity, price, and conditions are all in accordance with the relevant laws, regulations, and the incentive plan [10][11].

Meeting Overview - The shareholders' meeting of Kaisheng Technology Co., Ltd. was held on June 13, 2025, at the company's office in Bengbu [1] - The meeting was attended by shareholders representing 30.1487% of the total shares [1] - The voting method combined on-site registered voting and online voting, complying with relevant laws and regulations [1] Voting Results - All proposed resolutions were approved with significant majority votes from A-shareholders, including: - Resolution 1: 99.5910% in favor [1] - Resolution 2: 98.4860% in favor [1] - Resolution 3: 98.4832% in favor [1] - Resolution 4: 98.4749% in favor [1] - Resolution 5: 98.4832% in favor [1] - The voting results showed a consistent trend of high approval rates across multiple resolutions, indicating strong shareholder support [2][3] Legal Compliance - The meeting's procedures, attendance qualifications, proposals, and voting processes were confirmed to be in compliance with the Securities Law, Company Law, and other relevant regulations [3] - The legal opinions provided by the witnessing lawyers affirmed the legality and validity of the resolutions passed during the meeting [3]

2024 年股票期权激励计划首次授予激励对象名单 （首次授权日） | 姓名 | | 职务 | 首次授予股票 期权数量（万 | 占首次授予股票 期权总数的比例 | 占首次授予日股本总 额比例 | | --- | --- | --- | --- | --- | --- | | | | | 份） | | | | 夏宁 | | 董事长、党委书记 | 16.90 | 1.04% | 0.02% | | 刘宇权 | | 董事、党委副书记、总经理 | 16.00 | 0.98% | 0.02% | | 张少波 | | 副总经理 | 15.00 | 0.92% | 0.02% | | 李蓓蓓 | | 党委副书记、纪委书记 | 15.00 | 0.92% | 0.02% | | 陈 | 幸 | 财务总监 | 15.00 | 0.92% | 0.02% | | 孙娜丽 | | 副总经理 | 15.00 | 0.92% | 0.02% | | 核心管理、业务及技术骨干（188 | | 人） | 1537.10 | 94.30% | 1.63% | | 首次授予权益数量合计（194 | | 人） | 1630.00 | 100.00 ...

证券代码：600552 证券简称：凯盛科技 公告编号：2025-027 凯盛科技股份有限公司 关于向 2024 年股票期权激励计划激励对象 首次授予股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 鉴于凯盛科技股份有限公司（以下简称"公司"）2024 年股票期权激励计划 （以下简称"本激励计划"、"激励计划"）规定的股票期权的授予条件已经成就， 根据公司 2025 年第二次临时股东大会授权，公司于 2025 年 6 月 13 日召开了第 九届董事会薪酬与考核委员会第二次会议、第九届董事会第四次会议，审议通过 了《关于向 2024 年股票期权激励计划激励对象首次授予股票期权的议案》，同 意以 2025 年 6 月 13 日为首次授权日。现将有关事项说明如下： 一、股票期权授予情况 （一）2024 年股票期权激励计划的决策程序和批准情况 1 股票期权首次授权日：2025 年 6 月 13 日 股票期权首次授予数量：1,630.00 万份 股票期权首次授予行权价格：12.08 元/份 表了同意的意 ...

证券代码：600552 证券简称：凯盛科技 公告编号：2025-028 凯盛科技股份有限公司 关于公司 2024 年股票期权激励计划 内幕信息知情人买卖公司股票情况的自查报告 二、核查对象买卖公司股票情况说明 根据中国证券登记结算有限责任公司上海分公司 2025 年 6 月 12 日出具的 《信息披露义务人持股及股份变更查询证明》《股东股份变更明细清单》，在自 查期间，共有 1 名核查对象存在买卖公司股票的行为，除上述人员外，其余核查 对象不存在买卖公司股票的情形。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2024 年 12 月 31 日，凯盛科技股份有限公司（以下简称"公司"）召开第八 届董事会第三十四次会议，审议通过了公司《2024 年股票期权激励计划（草案）》 及其摘要等相关议案，并于 2025 年 1 月 1 日在上海证券交易所网站披露了相关 公告。 按照《上市公司股权激励管理办法》（以下简称《管理办法》）、《上市公 司信息披露管理办法》《上海证券交易所上市公司自律监管指引第 2 号——信息 披露事务管理 ...

证券代码：600552 证券简称：凯盛科技 公告编号：2025-026 （二）2025年5月20日，公司披露了《凯盛科技股份有限公司关于2024年股 票期权激励计划获得批复的公告》，公司收到控股股东凯盛科技集团有限公司印 发的《关于凯盛科技股份有限公司实施股票期权激励计划的批复》（凯盛发改革 [2025]3号）文件，经国务院国资委同意，原则同意公司实施2024年股票期权激 励计划。 （三）公司内部对激励对象名单进行了公示，公示期自2025年5月27日至2025 年6月5日。公示期满后，监事会对本次激励计划首次授予激励对象名单进行了核 1 查，并于2025年6月7日出具了《监事会关于2024年股票期权激励计划首次授予激 励对象名单的核查意见及公示情况说明》。 （四）2025年6月13日，公司召开了2025年第二次临时股东大会，审议并通 过了《关于审议公司<2024年股票期权激励计划（草案）>及其摘要的议案》、《关 于制定公司<2024年股票期权激励计划管理办法>的议案》、《关于制定公司<2024 年股票期权激励计划实施考核管理办法>的议案》、《关于提请股东大会授权董 事会办理公司2024年股票期权激励计划相关事 ...

3、获授权益的激励对象不存在《管理办法》规定的不得成为激励对象的情 形： （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； 凯盛科技股份有限公司 薪酬与考核委员会关于公司 2024 年股票期权激励计划 激励对象名单（首次授权日）的核查意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）以及《公司章程》等有关法律法规及规范性文件的规定，凯盛 科技股份有限公司（以下简称"公司"）薪酬与考核委员会对公司本次股票期权 激励计划授权日的激励对象名单进行审核。现发表核查意见如下： 1、本激励计划激励对象人员名单与公司 2025 年第二次临时股东大会审议通 过的《凯盛科技股份有限公司 2024 年股票期权激励计划（草案）》中规定的激 励对象一致。 2、获授权益的激励对 ...

证券代码：600552 证券简称：凯盛科技 上海荣正企业咨询服务（集团）股份有限公司 关于 凯盛科技股份有限公司 2024 年股票期权激励计划 首次授予相关事项 之 一、释义 | 公司、本公司、凯盛科技 | 指 | 凯盛科技股份有限公司 | | --- | --- | --- | | 激励计划、本激励计划、本计划 | 指 | 凯盛科技股份有限公司 年股票期权激励计划 2024 | | 本草案、本激励计划、草案 | 指 | 凯盛科技股份有限公司 年股票期权激励计划（草案） 2024 | | 股票期权、期权 | 指 | 公司授予激励对象在未来一定期限内以预先确定的价格和条件 购买本公司一定数量股票的权利 | | 激励对象 | 指 | 按照本计划规定，获得股票期权的公司董事、高级管理人员和 核心管理、业务及技术骨干 | | 授权日 | 指 | 公司向激励对象授予股票期权的日期，授权日必须为交易日 | | 等待期 | 指 | 股票期权授权日至股票期权可行权日之间的时间段 | | 有效期 | 指 | 自股票期权首次授权日起至激励对象获授的股票期权全部行权 或注销完毕之日止 | | | | 激励对象根据股票期权激励计划， ...